Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
They are: 98% more likely to have a psychiatric disorder 195% higher risk of depression at a 9X higher risk of pancreatitis 3.7X more likely to have gastroparesis 4X higher risk of developing a bowel obstruction The combination of a high incidence of side effects, a lack of patient education, an increased risk for both physical and mental health disorders, and the rising demand for GLP-1s has created the perfect storm for patients who find themselves experiencing debilitating side effects without the knowledge of how to control them
This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access $259.00 per year only $21.58 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
& Edison, P
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial
US$ 24.68
US$ 24.51
US$ 23.40
US$ 20.18
US$ 25.11
